Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Stage IV EGFR Mutated Non-Small Cell Lung Cancer
and you are
between 18 and 99
years old
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

To tested if the adding of consolidative SBRT to TKI in EGFR mutated patients with less than or equal to 5 metastatic sites (primary + 5) will improve progression free survival (PFS) compared to TKI alone.

Provided treatments

  • Radiation: Radiation: SBRT
  • Drug: TKI (Gefitinib or Tarceva )
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02893332. The sponsor of the trial is Sichuan Provincial People's Hospital and it is looking for 200 volunteers for the current phase.
Official trial title:
Tyrosine-kinase Inhibitor (TKI) With or Without SBRT in Newly Diagnosed EGFRm Advanced Staged Lung Adenocarcinoma